New diagnostic and therapeutic tools against multidrug resistant tumors - COST ACTION CA17104 (STRATAGEM)

Overview

Project Summary

This groundbreaking initiative forms a diverse network of academic labs, research institutes, and SMEs to enhance the diagnosis and therapy of multidrug-resistant (MDR) solid tumors. 

Addressing fragmented knowledge and the lack of predictive algorithms, the focus is on creating an open platform for MDR tumor insights, identifying biomarkers, and developing safe compounds for personalized treatments. With 70% of solid tumors resistant at diagnosis, the initiative aims to improve patient outcomes, reduce healthcare costs, and stimulate collaborations between basic and industrial research, fostering the growth of Start-ups and SMEs in Europe. Additionally, the initiative elevates European research standards on MDR, narrowing the quality gap and prioritizing training for Early Career Investigators as future research leaders.

Project Details